Scinai Immunotherapeutics Ltd. Sponsored Adr ( (SCNI) ) has released its Q1 earnings. Here is a breakdown of the information Scinai Immunotherapeutics Ltd. Sponsored Adr presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company engaged in developing innovative biological drug candidates for inflammation and immunology-related diseases and providing contract development and manufacturing organization (CDMO) services.
In its latest earnings report for the first quarter of 2025, Scinai highlighted strong revenue momentum in its CDMO business and a significant reduction in cash burn. The company reported revenues of $586,000 for the quarter, reflecting a year-over-year increase driven by a higher number of contracts in its CDMO unit.
Key financial metrics from the report include a decrease in research and development expenses to $1,296,000, down from $1,568,000 in the same period last year, primarily due to lower wages and direct R&D costs. Marketing, general, and administrative expenses saw a slight increase to $500,000. Notably, the company achieved a net financial income of $11,000, a significant improvement from a financial expense of $231,000 in the previous year, attributed to the conversion of a loan into preferred shares. The net loss for the quarter was reduced to $1,557,000 from $2,159,000 a year earlier.
Looking ahead, Scinai’s management remains focused on expanding its CDMO business and advancing its pipeline of nanosized VHH antibodies targeting diseases with large unmet medical needs. The company aims to continue building on its recent financial performance and strategic initiatives.